Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Future Oncol. 2013 Feb;9(2):255-69. doi: 10.2217/fon.12.173.
It has been found that the epigenetic silence of tumor suppressor genes induced by overexpression of histone deacetylases (HDACs) plays an important role in carcinogenesis. HDAC inhibitors (HDACi) that block the activity of specific HDACs have emerged as the accessory therapeutic agents for multiple human cancers. To better understand the effects of HDACi in cancer treatment, we carried out a review based on 30 published clinical trials to determine whether HDACi will benefit patients with solid tumors. Information of complete response, partial response, stable disease, objective responses and objective response rate was collected to assess clinical outcomes. A lack of therapeutic effects was observed when HDACi was used as a single agent. However, when HDACi treatment was combined with other agents, it appeared to increase the anti-tumor activity. High-quality studies are required to better understand the clinical effects of HDACi.
研究发现，组蛋白去乙酰化酶（HDACs）过度表达诱导的肿瘤抑制基因表观遗传沉默在肿瘤发生中起重要作用。HDAC 抑制剂（HDACi）可阻断特定 HDAC 的活性，已成为多种人类癌症的辅助治疗药物。为了更好地了解 HDACi 在癌症治疗中的作用，我们基于 30 项已发表的临床试验进行了综述，以确定 HDACi 是否会使实体瘤患者受益。我们收集了完全缓解、部分缓解、疾病稳定、客观反应和客观反应率的信息，以评估临床结果。结果显示，HDACi 作为单一药物使用时疗效不佳。然而，当 HDACi 治疗与其他药物联合使用时，似乎可以增加抗肿瘤活性。需要高质量的研究来更好地了解 HDACi 的临床效果。
Zotero 插件